nach oben

Erschienen in:

01.02.2023 | Clinical study

No increased risk of CV events or mortality with roxadustat vs ESA in CKD anaemia

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Roxadustat is not associated with an increased risk of cardiovascular (CV) events or mortality, compared with an erythropoiesis-stimulating agent (ESA), in patients with chronic kidney disease (CKD) and anaemia. …

Funding for this study and its publication was provided by Astellas Pharma, Inc.

Barratt J, et al. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Advances in Therapy : 7 Feb 2023. Available from: URL: http://doi.org/10.1007/s12325-023-02433-0

Titel: No increased risk of CV events or mortality with roxadustat vs ESA in CKD anaemia
Publikationsdatum: 01.02.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-33530-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Alendronic-acid/zoledronic-acid

Azacitidine

Tisagenlecleucel

Multiple drugs

Azd-1222/methylprednisolone/prednisone

Multiple drugs